Navigation Links
Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT

H. Lee Moffitt Cancer Center & Research Institute, working in partnership with the University of South Florida (USF), has discovered a new use for an old, previously discredited anti-cancer drug that could add another weapon in the arsenal against several cancers, including tumors of the breast, ovary, colon, skin and prostate.

The compound, tricirbine, was tested at various cancer centers from 1982 to 1996 and found to inhibit some cancers, but researchers failed to determine why. The Moffitt-USF team discovered that tricirbine works only against tumors in which the cancer-causing Akt protein is abundant and/or abnormally active.

"These tumors are addicted to hyperactive Akt and cannot survive without it," explains Saïd Sebti, Ph.D., Moffitt's Manuel and Adeline Garcia Professor, Leader of the Drug Discovery Program and Associate Director of Moffitt Research Institute. "What we discovered is a tailored therapy for tumors with a specific molecular signature."

Resurrecting tricirbine may be promising for patients with ovarian cancer, for instance, because "40 percent of women with ovarian cancer have tumors with high levels of active Akt," according to Sebti.

"To our knowledge, this is the first Akt inhibitor headed toward clinical trials," said Jin Cheng, MD, PhD, USF Professor of Pathology and Interdisciplinary Oncology.

Cheng and Sebti's study results were published in the journal Cancer Research.

VioQuest Pharmaceuticals Inc. (VQPH) of New Jersey is acquiring the licensing rights to the compound from USF through its merger with Greenwich Therapeutics Inc. and is planning clinical trials with Moffitt. The trials are expected to start within six to eight months. Patients will be selected for the trials based on whether their tumors have hyperactive Akt, which can be determined by a simple slide-stain test of tumor tissue.

Because tricirbine has previously been investigated in humans, the hypothesis-driven c linical trials planned at Moffitt can move directly into a PhaseI/II trial.

With the step-up of functional-genomics research at Moffitt and around the country, the advent of "customized medicine" has been heralded in headlines and at medical conferences. The clinical trial of this Akt-inhibitor is a concrete step toward that reality. Sebti says, "The beauty of this trial is that it's molecular therapy, based on the blueprint of the tumor cell."


'"/>

Source:University of South Florida Health Sciences Center


Related biology news :

1. Unchecked DNA replication drives earliest steps toward cancer
2. Virologists make major step towards understanding the process of HIV infection
3. Cats indifference towards sugar explained
4. A step toward the $1,000 personal genome using readily available lab equipment
5. A new step towards an AIDS vaccine
6. New GM mosquito sexing technique is step towards malaria control, report scientists
7. Novel method reveals how menthol discovery could point towards new or improved pain therapies
8. Scientists make first step towards holy grail of crystallography
9. Salk researchers make fast strides towards understanding how our body controls walking
10. Illegal trade is propelling rare turtle toward extinction, new report
11. Iraqs marshes show progress toward recovery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports the ... Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over the ... Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
(Date:2/10/2016)... ... ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused on the discovery and ... been selected to present at the Cavendish Global Health Impact Forum taking place February ... of the Forum is to help family offices and foundations develop and implement their ...
(Date:2/9/2016)... ... ... With a presidential election in November and the future of U.S. healthcare in ... top healthcare leaders for a night and day of debates and discussions about what ... the University of Pennsylvania’s Wharton School, will be held February 18 – 19, 2016 ...
Breaking Biology Technology: